Themis MedicareQ4 FY23

Themis Medicare Q4 FY23 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹95.93Market Cap: ₹884 CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

Yes

2 of 3 growth signals are positive.

Full analysis

Revenue guidance

Category 2
  • Themis Medicare expects a 35% CAGR growth over the next 2-3 years, driven primarily by hospital business expansion.
  • Growth in hospital business is supported by building and adding specialized sales teams focused on hospitals.
  • New product launches, including generics for emerging markets and new drug delivery systems, are planned but will take time due to regulatory approvals.
  • The critical care portfolio is being developed steadily, with plans to introduce more teams and products over the next 3-4 years.
  • Export markets remain a focus, targeting 40+ emerging markets with high-value generics.
  • API business is expected to show improvement with a new manufacturing process.
  • Domestic formulation business aims for first-launch opportunities with improved margins.
  • Overall growth will leverage increased productivity without a significant rise in fixed sales force costs.

See what Themis Medicare management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • The company has taken on additional long-term borrowing (an increase of INR5 crore) in the form of a term loan from current bankers.
  • This borrowing is meant to fund the ongoing capex plan, including facility upgrades in Haridwar, setting up R&D labs, and construction activities.
  • There is no explicit mention of any planned new equity fundraising.
  • The focus appears to be on organic growth supported by internal capex and operational improvements rather than fresh equity infusion.
  • No specific details were shared about future debt or equity fundraising beyond the current term loan for capex.

See what Themis Medicare management said on order book — free account, 30 seconds.

Capex plans

Yes
  • FY23 capex totaled around INR 29 crores (net of depreciation), invested in:
  • - Upgrading Haridwar facility (~INR 14.65 crores) for EU GMP compliance and additional injectable lines.
  • - Enhancing Vapi factory capacity (~INR 11 crores).
  • - Increasing R&D base in Hyderabad and setting up a new R&D lab in Baroda (~INR 1.17 crores).
  • - Plant and machinery additions and building construction for refinement projects.
  • Capex funded partly through increased long-term borrowing (~INR 5 crores term loan).
  • Focus on strategic investments to support growth areas:
  • - Injectable line upgrades and obtaining UDMP certification to open export opportunities.
  • - Building critical care product portfolio aligned with hospital business focus.
  • - Strengthening R&D with skilled manpower and infrastructure to drive future product development.
  • Future investments expected to support expansion in hospital and API businesses, with a cautious approach to fixed costs.

Track Themis Medicare — get its next earnings analysis in your feed

How does Themis Medicare rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisThemis Medicare
Rev 2Mar 1

How does Themis Medicare rank in Pharmaceuticals & Biotechnology?

Compare Themis Medicare against every Pharmaceuticals & Biotechnology company (Q4 FY23) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

  • Alpa Laboratorie (Q2 FY27)

    Standalone: ₹3,097.56 lacs . Key results statement takeaways from Alpa Laboratories Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →